Abstract:BACKGROUND:There is little evidence of combining sorafenib with hepatic arterial infusion chemotherapy (HAIC) after transarterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC). It is important to identify that patients with intermediate and advanced HCC are most likely to benefit from this combination therapy. AIM:To investigate the safety and clinical outcomes of sorafenib combined with HAIC with folinic acid, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX) after TACE for intermediate and advanced HCC. METHODS:This prospective phase II study enrolled patients with intermediate and advanced HCC who underwent treatment with sorafenib combined with TACE-HAIC. All patients initially received the standard 400 mg dose of sorafenib twice daily before TACE-HAIC. Participants at our institute with intermediate and advanced HCC underwent routine TACE. Then, the catheter used for embolization was kept in place in the hepatic artery, and oxaliplatin was intra-arterially administered for 6 h, followed by 5-FU for 18 h, and folinic acid was intravenously administered for 2 h. The primary endpoints were safety, as evaluated by the Common Terminology and Criteria for Adverse Events version 4.0, and 12-mo progression-free survival (PFS), as analyzed by the Kaplan-Meier method. As secondary endpoints, the objective response rate (ORR) was evaluated by the modified Response Evaluation Criteria for Solid Tumors, and survival time [overall survival (OS)] was analyzed by the Kaplan-Meier method. RESULTS:Sixty-six participants at our institute with intermediate and advanced HCC were enrolled in this prospective study (mean age, 53.3 ± 11.7 years). Approximately 56.1% of participants had Barcelona Clinic Liver Cancer (BCLC) stage C disease, and 43.9% had BCLC stage B disease. The ORR was 42.4%. The disease control rate was 87.9%. The grade 3-4 toxicities consisted of thrombocytopenia (4.5%), neutropenia (3.0%), and elevated aspartate aminotransferase (12.2%). Hand-foot skin reaction was also observed (40.9%). The median PFS was 13.1 mo (13.5 mo in the BCLC stage B participants and 9.4 mo in the BCLC stage C participants). The 6-mo, 12-mo, and 24-mo PFS rates were 75.0%, 54.7%, and 30.0%, respectively. The median OS was 21.8 mo. CONCLUSION:Sorafenib combined with HAIC (FOLFOX) after TACE may be a feasible treatment choice for intermediate and advanced HCC because this treatment met the prespecified endpoint of a 6-mo PFS rate exceeding 50% and had good patient tolerance. Prospective randomized controlled trials are needed to confirm the effect of this combination therapy.

Effects of Sorafenib Combined with Chemoembolization and Radiofrequency Ablation for Large, Unresectable Hepatocellular Carcinomas

Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma

[The Analysis of the Efficacy and Safety of Combined Transarterial Chemoembolization with Sorafenib in Patients with Large Hepatocellular Carcinoma].

Triple Strategies of Sorafenib Combined with Chemoembolization and Radiofrequency Ablation for Large, Unresectable Hepatocellular Carcinomas: a Pilot Study

[Clinical Analysis of the Treatment:Transcatheter Arterial Chemoembolization Combined with Sorafenib in Advanced Hepatocellular Carcinoma].

Enhanced Therapeutic Efficacy of Combined Use of Sorafenib and Transcatheter Arterial Chemoembolization for Treatment of Advanced Hepatocellular Carcinoma.

Percutaneous Radiofrequency Ablation Combined With Transarterial Chemoembolization Plus Sorafenib for Large Hepatocellular Carcinoma Invading the Portal Venous System: A Prospective Randomized Study

Efficacy and Prognostic Factors of Sorafenib Targeted Therapy for Advanced Hepatocellular Carcinoma

Effect of the Combination Therapy of Sorafenib and Radiofrequency Ablation on the Survival Time of Advanced Hcc.

Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.

The Long-Term Efficacy of Combined Chemoembolization and Local Irradiation in the Treatment of Patients with Large Hepatocellular Carcinoma.

Advantage of Sorafenib Combined with Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma

Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma

Transarterial Chemoembolization Combined with Sorafenib for the Treatment of Hepatocellular Carcinoma with Hepatic Vein Tumor Thrombus

Prognosis Comparison Between Surgical Treatment and Transcatheter Arterial Chemoembolization Combined with Sorafenib in Patients with Advanced Hepatocellular Carcinoma

Effect and Safety of Sorafenib in Patients with Intermediate Hepatocellular Carcinoma Who Received Transarterial Chemoembolization: A Retrospective Comparative Study.

Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma]

The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Tu1488 - Sorafenib with or without Transarterial Chemoembolization Plus Radiofrequency Ablation for Advanced Recurrent Hepatocellular Carcinoma

Sorafenib Combined with Embolization Plus Hepatic Arterial Infusion Chemotherapy for Inoperable Hepatocellular Carcinoma.

Observation of Curative Effect of Sorafenib for Patients with Advanced Hepatocellular Carcinoma